The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).
Andrea P. Myers
Consultant or Advisory Role - Sanofi
Russell Broaddus
No relevant relationships to disclose
Vicky Makker
No relevant relationships to disclose
Panagiotis A. Konstantinopoulos
No relevant relationships to disclose
Ronny Drapkin
No relevant relationships to disclose
Neil S. Horowitz
No relevant relationships to disclose
Joyce Liu
No relevant relationships to disclose
Paul Van Hummelen
No relevant relationships to disclose
Funda Meric-Bernstam
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Robert L. Coleman
Consultant or Advisory Role - Arno Therapeutics; AstraZeneca; MedImmune; Merck
Research Funding - Esperance Pharmaceuticals; Johnson & Johnson; Merck; NCI
Carol Aghajanian
No relevant relationships to disclose
Gordon B. Mills
No relevant relationships to disclose
Lewis Cantley
Employment or Leadership Position - Bristol-Myers Squibb
Consultant or Advisory Role - Novartis
Stock Ownership - Bristol-Myers Squibb (B); Vertex (B)
Honoraria - Genentech; Infinity; Novartis
Research Funding - GlaxoSmithKline; Pfizer
Ursula A Matulonis
No relevant relationships to disclose
Shannon Neville Westin
No relevant relationships to disclose